
    
      Subjects are dosed with Bortezomib and PLD for a maximum of 6 cycles of 4 weeks. The response
      rate is evaluated with CT according to RECIST criteria ver 1.1. The efficacy and safety of
      the drug are assessed at the time of recurrence, at the time of death, or after 24 months
      after the end of the study drug administration.
    
  